Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
osimertinib (tagrisso) (1 trial)
aumolertinib (1 trial)
erlotinib (tarceva) (1 trial)
glumetinib (1 trial)
carboplatin (paraplatin) (1 trial)
gefitinib (iressa) (1 trial)
pemetrexed (alimta) (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Lung Neoplasms (Phase 3)
Trials (5 total)
Trial APIs (7 total)